Haemonetics to acquire Attune Medical for $160M upfront; device complements EP portfolio

HAEMONETICS CORP

Upfront cash $160M plus contingent consideration based on sales growth and milestones.
Attune Medical's ensoETM device reduces esophageal injury during cardiac ablation; revenue $22M in 2023, doubled YoY.
Transaction expected to close in Q1 fiscal 2025 (April-June 2024) subject to customary conditions.
Haemonetics expects immediate accretion to revenue and earnings growth; financed via cash and revolver.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.